Who mentions $AMGN most on Surfaced?

@jacobplieth (Jacob Plieth) mentions $AMGN most — 17 mentions in the past 12 months.

When was $AMGN first mentioned on Surfaced?

The earliest tracked mention of $AMGN in the Surfaced archive was on Sep 4, 2025.

How many voices track $AMGN?

3 FinTwit voices have mentioned $AMGN 26 times in the past 12 months.

What kind of voices mention $AMGN most?

$AMGN is mentioned most by Biotech voices on Surfaced.

$AMGN — FinTwit mentions on Surfaced

Recent mentions

27 mentions

@jacobpliethMay 8, 2026 · 12:10 PM

Backing for $ZLAB's DLL3 + DLL3 efforts? $AMGN https://t.co/rRkvNepL11

Open on X

@jacobpliethApr 30, 2026 · 11:34 AM

Krystal-10 was the (delayed) confirmatory trial, so does the FDA now rescind Krazati's accelerated approval in colorectal cancer? $BMY $AMGN

Open on X

@adamfeuersteinApr 28, 2026 · 7:29 PM

FDA launches effort with $AZN $AMGN to speed up clinical trials, using AI https://t.co/k4LjxnDLmq via @LizzyLaw_

Open on X

@jacobpliethApr 15, 2026 · 1:05 PM

Next, why not run a trial combining Imdelltra + zoci-P + obrixtamig? Any scientific reason not to? $AMGN $ZLAB

Open on X

@jacobpliethApr 1, 2026 · 12:25 PM

Ha ha, great April Fool's joke from $ZLAB $AMGN! https://t.co/HlXz61yXa9

Open on X

@jacobpliethMar 18, 2026 · 4:24 PM

$MRK's PD-1 x VEGF bispecific reveal, & other key #AACR26 presentations, via @APEXONCO -> https://t.co/ob1eswxCWF $RVMD $AMGN $GILD $BCYC $SDGR

Open on X

@jacobpliethMar 18, 2026 · 10:17 AM

$AMGN's likely discontinued anti-CCR8 MAb #AACR26

Open on X

@jacobpliethMar 16, 2026 · 2:37 PM

Since my 2024 look at CCR8 a lot has happened: $BMY $GILD $ABBV upsized; $ONC Bayer $ZLAB (& soon $AMGN?) discontinued. @BatirtzeAreitio investigates, via @ApexOnco -> https://t.co/hUweyScpAN $CHRS $RHHBY

Open on X

@jacobpliethFeb 26, 2026 · 12:33 PM

$RVMD was collaborating with $TNGX in PRMT5, but now it's working with $BMY (remember that ex MRTX project?). Via @ByMadeleineA @ApexOnco -> https://t.co/mGZjKOiB7p (And $AMGN still dose optimising.)

Open on X

@adamfeuersteinFeb 3, 2026 · 9:10 PM

$AMGN Tavneos update. FDA wants it pulled from the market. On January 16, 2026, the U.S. Food and Drug Administration (FDA) requested that ChemoCentryx voluntarily withdraw TAVNEOS from the U.S. market. The FDA raised concerns about the process followed by ChemoCentryx to re-adjudicate primary endpoint results for 9 of the 331 patients in its pivotal clinical trial. Hepatotoxicity, which is a known infrequent risk of TAVNEOS treatment for AAV, was also raised in the context of the benefit-risk profile of the medicine. Amgen is not aware of any issue with the underlying patient data from the ChemoCentryx clinical trial. And after review of the relevant clinical data and years of real-world evidence, Amgen is confident that TAVNEOS demonstrates effectiveness and a favorable benefit–risk profile. On January 28, 2026, following FDA regulatory process, Amgen informed the Agency that it did not intend to withdraw TAVNEOS from the market. Amgen is evaluating next steps with the FDA to determine a path forward, while keeping patient safety, needs and support at the forefront.

Open on X

@adamfeuersteinFeb 2, 2026 · 12:52 PM

Another OX40 update, and it's not good. On an analyst call Sunday, Kyowa Kirin disclosed a case of Karposi's sarcoma with rocatinlimab in a "high risk" patient, according to a Jefferies note. Recall, last week, $AMGN returned roca to Kyowa.

Open on X

@jasonl_capitalFeb 2, 2026 · 11:32 AM

ALL OF THESE STOCKS REPORT EARNINGS THIS WEEK! Monday, February 2: The Walt Disney Company $DIS Palantir Technologies $PLTR NXP Semiconductors $NXPI Simon Property Group $SPG Tyson Foods $TSN Teradyne $TER Tuesday, February 3: Advanced Micro Devices $AMD Super Micro Computer $SMCI Pfizer $PFE Merck $MRK Chipotle Mexican Grill $CMG PepsiCo $PEP PayPal $PYPL Shopify $SHOP Amgen $AMGN Ferrari $RACE Wednesday, February 4 Alphabet $GOOGL Eli Lilly $LLY Novo Nordisk $NVO Uber Technologies $UBER Arm Holdings $ARM Qualcomm $QCOM Lantronix $LTRX EnerSys $ENS Snapchat $SNAP Shopify $SHOP AbbVie $ABBV Thursday, February 5 Amazon $AMZN Reddit $RDDT Shell $SHEL Roblox $RBLX MicroStrategy $MSTR IREN $IREN Unity Software $U Friday, February 6 Johnson Outdoors $JOUT Clean Energy Fuels $CLNE

Open on X

@adamfeuersteinJan 30, 2026 · 2:31 PM

And now $AMGN returns its OX40 drug candidate rocatinlimab to Kyowa.

Open on X

@adamfeuersteinJan 30, 2026 · 12:47 PM

What's this about? EMA re-reviewing $AMGN Tavneos due to "data integrity" issues in study that supported approval. https://t.co/lg9eh7qSmJ

Open on X

@adamfeuersteinJan 23, 2026 · 2:51 PM

Leerink's David Risinger on the $SNY amlitelimab Karposi's sarcoma case: "As a result, we see risk of a potential black box warning on amlitelimab’s label." Would be same for $AMGN $APGE and any other company with an OX40 drug, right?

Open on X

@adamfeuersteinJan 23, 2026 · 12:23 PM

Perhaps I am over-reacting, but doesn't the reported case of Kaposi's sarcoma in the $SNY amlitelimab atopic dermatitis study basically end any hope for the entire OX40 drug class? $AMGN included. Why would any patient or physician take the risk with an OX40 drug when there are so many other better treatment options?

Open on X

@jacobpliethJan 6, 2026 · 2:05 PM

Dark Blue Therapeutics pipeline, via OncologyPipeline $AMGN https://t.co/WM4ft5n2c8

Open on X

@jacobpliethJan 2, 2026 · 1:30 PM

Funny $ABBV saying absolutely nothing about paying Zelgen $100m for a DLL-3 T-cell engager (H/T @chuminhua432). @ByMadeleineA earlier take on this biparatopic T-cell engager -> https://t.co/nm9YAZ3DUF $AMGN

Open on X

@jacobpliethDec 22, 2025 · 2:00 PM

$AZN follows $LLY $PFE $AMGN $ONC & $ALPMF into pan-KRAS, but should it be looking more to pan-RAS approaches like $RVMD & $ERAS? Via @ApexOnco -> https://t.co/MioOWziuSt

Open on X

@jacobpliethDec 22, 2025 · 12:09 PM

@NotGenentech @bioinvestor24 Here's a list of just the clinical pan-RAS & pan-KRAS assets from Oncologypipeline $RVMD $LLY $ONC $RHHBY $PFE $ERAS $AZN $AMGN $ALPMF https://t.co/oeb4Yr2nzo

Open on X

@adamfeuersteinNov 8, 2025 · 3:41 PM

#AHA25 reporting all weekend Amgen’s $AMGN cholesterol shot prevented first heart attacks and strokes, more detailed data affirm https://t.co/1RX6TrfU6l via @cooney_liz

Open on X

@jacobpliethSep 24, 2025 · 8:52 PM

Apparently #SITC25 is hosting a webinar on development of anti-CCR8 MAbs - mechanisms & clinical results. 22 Oct 2025 $CHRS $BMY $ABBV $RHHBY $AMGN $GILD $BGNE $FGEN $BNTX

Open on X

@adamfeuersteinSep 18, 2025 · 1:19 PM

This week's Biotech Scorecard newsletter: - $SGMO 's Fabry therapy partner search looks futile - Geoff Porges is back on Wall Street, taking a banking role at Lazard - Don't get rid of FDA adcomms, make them better. I have a few ideas, including: Eliminate the public hearing where patients and advocates basically intimidate experts into voting yes, even when the data say otherwise. - Comments from Peter Marks and $AMGN at a recent conference. Link to web version of the newsletter below.

Open on X

@jacobpliethSep 4, 2025 · 12:57 PM

But it's not clear how bad the OS decline has been from interim -> final analysis. $AMGN Paul Burton @ W Fargo: "at a recently completed final analysis the magnitude of the survival benefit has decreased". That's all we know $ZLAB

Open on X

@jacobpliethSep 4, 2025 · 8:51 AM

Story from @ByMadeleineA from when Fortitude-101 was toplined in June. Clearly tox is now a major factor https://t.co/Ha0bNZinlY $AMGN $ZLAB

Open on X

@jacobpliethSep 4, 2025 · 8:50 AM

Wow, so $AMGN slipped out that bemarituzumab's positive final OS analysis slipped into negative territory at longer follow-up. $ZLAB off 6% yesterday, -4% premarket today https://t.co/W6TdNDHlzj

Open on X

@jacobpliethJun 30, 2025 · 1:09 PM

$AMGN Fortitude-101 study of bemarituzumab (ex $FPRX) + chemo is stat sig "& clinically meaningful" for OS vs chemo alone. FGFR2b overexpression (≥10% @ IHC 2+/3+) was enrolment criterion, I believe, so this is a hit on ITT. $TYRA

Open on X

$AMGN

$AMGN

About this stock

Related stocks

Frequently asked